Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity

BACKGROUND: Although immune checkpoint inhibitors have been a breakthrough in clinical oncology, these therapies fail to produce durable responses in a significant fraction of patients. This lack of long-term efficacy may be due to a poor pre-existing network linking innate and adaptive immunity. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez-Rodriguez, Laura, Cianciaruso, Chiara, Bill, Ruben, Trefny, Marcel P, Klar, Richard, Kirchhammer, Nicole, Buchi, Mélanie, Festag, Julia, Michel, Sven, Kohler, Rainer H, Jones, Elham, Maaske, Andre, vom Berg, Johannes, Kobold, Sebastian, Kashyap, Abhishek S, Jaschinski, Frank, Dixon, Karen O, Pittet, Mikael J, Zippelius, Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201251/
https://www.ncbi.nlm.nih.gov/pubmed/37208130
http://dx.doi.org/10.1136/jitc-2023-006714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201251/
https://www.ncbi.nlm.nih.gov/pubmed/37208130
http://dx.doi.org/10.1136/jitc-2023-006714

Ejemplares similares